{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:11:08Z","timestamp":1768000268899,"version":"3.49.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05025-x","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:14:32Z","timestamp":1715570072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial"],"prefix":"10.1007","volume":"42","author":[{"given":"Rong","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-0782","authenticated-orcid":false,"given":"Changkai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"5025_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00345-024-04799-4","volume":"42","author":"N Wada","year":"2024","unstructured":"Wada N, Mizunaga M, Abe N et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42:113. https:\/\/doi.org\/10.1007\/s00345-024-04799-4","journal-title":"World J Urol"},{"key":"5025_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2023.05.014","volume":"84","author":"F Farag","year":"2023","unstructured":"Farag F, Sakalis VI, Arteaga SM et al (2023) What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the european association of urology, female non-neurogenic lower urinary tract symptoms guidelines panel. Eur Urol 84:302\u2013312. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.014","journal-title":"Eur Urol"},{"key":"5025_CR3","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/nau.24361","volume":"39","author":"T Tarcan","year":"2020","unstructured":"Tarcan T, Selai C, Herve F et al (2020) Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: ICI-RS 2019? Neurourol Urodyn 39:S70\u2013S79. https:\/\/doi.org\/10.1002\/nau.24361","journal-title":"Neurourol Urodyn"},{"key":"5025_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","volume":"175","author":"M Kinjo","year":"2023","unstructured":"Kinjo M, Masuda K, Nakamura Y et al (2023) Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175:67\u201373. https:\/\/doi.org\/10.1016\/j.urology.2023.02.003","journal-title":"Urology"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05025-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:30:41Z","timestamp":1735853441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05025-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5025"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05025-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Changkai Deng declares that he has no confict of interest. Author Rong Dai declares that she has no confict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"316"}}